Anika Therapeutics (ANIK) Cash from Operations (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash from Operations data on file, last reported at 4846000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 3627.69% year-over-year to 4846000.0 in Q1 2026; TTM through Mar 2026 was 6472000.0, a 19.87% increase from a year earlier, with the FY2025 full-year figure at 11188000.0, up 107.07% from the prior year.
• Cash from Operations for Q1 2026 stood at 4846000.0, down from 4637000.0 in the prior quarter.
• Over the last five years, Cash from Operations for ANIK reached as high as 6870000.0 in Q3 2025 and fell as low as 8293000.0 in Q2 2023.
• Historically, Cash from Operations has averaged 845058.82 across 5 years, with a median of 481000.0 in 2022.
• Across the five-year window, Cash from Operations jumped 656.34% in 2023 and slumped 3627.69% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 481000.0 in 2022, then soared by 656.34% to 3638000.0 in 2023, then plunged by 56.51% to 1582000.0 in 2024, then soared by 193.11% to 4637000.0 in 2025, then plunged by 204.51% to 4846000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 4846000.0 in Q1 2026, 4637000.0 in Q4 2025, and 6870000.0 in Q3 2025.